Sector News

Gilead's John Martin steps out of CEO role

February 1, 2016
Life sciences

(BUSINESS WIRE) – Gilead Sciences, Inc. today announced that, effective March 10, 2016, current Chairman and CEO John C. Martin, PhD will assume the role of Executive Chairman of the company.

John F. Milligan, PhD, currently President and Chief Operating Officer, will be promoted to CEO and appointed to the company’s Board of Directors.

John Martin joined Gilead in 1990 and was appointed Chief Executive Officer in 1996 and Chairman of the Board in 2008. John Milligan also joined Gilead in 1990 and was appointed Chief Operating Officer in 2007 and President in 2008.

“John Martin has led Gilead as CEO for the past 20 years, and under his stewardship, the company has developed and delivered therapeutic advancements to millions of people around the world. His legacy is clear – and the vision he has set will continue with his contributions as Executive Chairman,” said John Cogan, PhD, Gilead’s Lead Independent Director.

“Over the past 25 years, John Milligan has distinguished himself as an exceptional leader, serving in diverse management roles and overseeing multiple phases of growth and expansion into new therapeutic areas and geographies. The Board of Directors and I are confident in his ability to lead Gilead into the future,” commented John Martin.

Source: Gilead Sciences

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach